Editas Medicine (EDIT) Revenue & Revenue Breakdown
Editas Medicine Revenue Highlights
Editas Medicine Revenue by Period
Editas Medicine Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $19.71M | -22.83% |
| 2021-12-31 | $25.54M | -71.85% |
| 2020-12-31 | $90.73M | 341.93% |
| 2019-12-31 | $20.53M | -35.71% |
| 2018-12-31 | $31.94M | 132.64% |
| 2017-12-31 | $13.73M | 126.80% |
| 2016-12-31 | $6.05M | 271.58% |
| 2015-12-31 | $1.63M | 100.00% |
| 2014-12-31 | - | - |
Editas Medicine generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Editas Medicine Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $1.14M | -98.11% |
| 2023-12-31 | $60.05M | 1025.36% |
| 2023-09-30 | $5.34M | 84.83% |
| 2023-06-30 | $2.89M | -70.69% |
| 2023-03-31 | $9.85M | 50.72% |
| 2022-12-31 | $6.54M | 15461.90% |
| 2022-09-30 | $42.00K | -99.34% |
| 2022-06-30 | $6.36M | -6.04% |
| 2022-03-31 | $6.77M | -45.70% |
| 2021-12-31 | $12.47M | 101.21% |
| 2021-09-30 | $6.20M | 1535.09% |
| 2021-06-30 | $379.00K | -94.17% |
| 2021-03-31 | $6.50M | -43.09% |
| 2020-12-31 | $11.42M | -81.83% |
| 2020-09-30 | $62.84M | 484.62% |
| 2020-06-30 | $10.75M | 87.82% |
| 2020-03-31 | $5.72M | -53.41% |
| 2019-12-31 | $12.28M | 219.23% |
| 2019-09-30 | $3.85M | 65.15% |
| 2019-06-30 | $2.33M | 12.61% |
| 2019-03-31 | $2.07M | -66.19% |
| 2018-12-31 | $6.12M | -57.86% |
| 2018-09-30 | $14.52M | 96.95% |
| 2018-06-30 | $7.37M | 87.73% |
| 2018-03-31 | $3.93M | 7.09% |
| 2017-12-31 | $3.67M | -41.63% |
| 2017-09-30 | $6.28M | 102.84% |
| 2017-06-30 | $3.10M | 354.11% |
| 2017-03-31 | $682.00K | -24.05% |
| 2016-12-31 | $898.00K | -6.65% |
| 2016-09-30 | $962.00K | -71.61% |
| 2016-06-30 | $3.39M | 320.87% |
| 2016-03-31 | $805.00K | 1.64% |
| 2015-12-31 | $792.00K | 18.21% |
| 2015-09-30 | $670.00K | 301.20% |
| 2015-06-30 | $167.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | - |
Editas Medicine generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Editas Medicine Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $9.84B | $2.65B |
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| DNA | Ginkgo Bioworks | $251.46M | $56.21M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| ALLO | Allogene Therapeutics | $95.00K | $22.00K |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | - |
| SANA | Sana Bio | - | - |
EDIT Revenue FAQ
What is Editas Medicine’s yearly revenue?
Editas Medicine's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $19.71M, representing a decrease of -22.83% compared to 2021. EDIT's yearly revenue for 2021 was $25.54M, representing a decrease of -71.85% compared to 2020.
What is Editas Medicine’s quarterly revenue?
Editas Medicine's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.14M, a -98.11% decrease from the previous quarter (Q4 2023), and a -88.48% decrease year-over-year (Q1 2023). EDIT's quarterly revenue for Q4 2023 was $60.05M, a 1025.36% increase from the previous quarter (Q3 2023), and a 818.74% increase year-over-year (Q4 2022).
What is Editas Medicine’s revenue growth rate?
Editas Medicine's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.